🇮🇪Ireland
16°C Partly Cloudy · Dublin
Live Updates
--:--:-- IST
Writer Login
Latest
Clinical Trials in the USA / NCT07744711
Enrolling by invitation Not applicable

Real-World Use of an iPad-Based Light Therapy App, With Optional Biomarker Collection

NCT07744711 · tracked via the Priya Life Science USA tracker
Sponsor
Circadian OS, Inc
Phase
Not applicable
Started
2026-07-17
Last updated
2026-08-04

Condition(s) studied

Circadian Rhythms

Investigational drug(s) / intervention(s)

Circadian OS iPad-based light app

Circadian OS iPad-based light app: Software-based light-delivery platform running on an off-the-shelf iPad. The app uses the display to deliver light targeting a specified circadian stimulus (CS ≥ 0.3), integrating spectrum and intensity at the eye. It runs closed-loop: screen luminance is calibrated in advance, the iPad camera tracks viewing distance and gaze direction, and the app computes the dose reaching the eye in real time, signaling whether the user is positioned to receive it. Session start-time recommendations are anchored to each participant's habitual wake time, derived from the Munich ChronoType Questionnaire. Onboarding presents a recommended envelope of approximately 60 minutes per day within approximately 2 hours of habitual wake. Use is not enforced and the app does not lock out off-envelope use. Participants use the app while streaming, reading, or browsing as they normally would.

Study summary

This study looks at how adults use an iPad-based light app in everyday life.

Light is the main signal that sets the body's internal clock, which controls daily rhythms in sleep, alertness, and many other body systems. Indoor living means many people do not get bright light at a consistent time each day.

The app uses the iPad screen to deliver light while people watch videos, read, or browse. It suggests about one hour of use per day, started within about two hours of waking. It does not require anyone to follow that schedule, and no one is locked out for using it more, less, or at other times. The app shows people when they are positioned to receive the intended light, records how the app is used, and asks short questions about sleep.

The main questions this study aims to answer are:

1. How often, how long, and at what time of day do people use the app?
2. What do people mostly do during light-delivery sessions?
3. What do people think of the app, and how easy is it to use?

Participants will use the app on an iPad for up to eight weeks, answer short questions about their sleep and how they feel, and share feedback about their experience.

Participants may also choose to take part in optional sub-studies. They can wear a device the sponsor provides to record movement, light exposure, and skin temperature, or share data from a wearable device they already use. They can also give blood, saliva, or urine samples, which researchers will use to describe daily patterns in clock-related genes and other markers. These sub-studies are entirely exploratory and voluntary, and participants can take part in the main study without them.

Participants will not receive results from any samples they give. This study does not provide medical treatment, and it is not designed to determine whether the app treats or improves any medical condition.

Eligibility

Sex
ALL
Min age
18 Years
Max age
Healthy volunteers
Accepted
Inclusion Criteria: * Adult 18 years of age or older * Able to read, understand, and provide written informed consent in English * Has access to a compatible iPad capable of running the study app for the duration of the exposure period, or is willing to use a Sponsor-supplied iPad * U.S. resident, able to be in the NYC metropolitan area for the study * Member of the Sponsor's network (friends, family, advisors, investors, employees, or contractors) * If opting in to the biomarker sub-study: weighs at least 110 lb (50 kg), and meets standard venipuncture eligibility on the day of collection Exclusion Criteria: * Diagnosed bipolar disorder, or history of light-induced manic or hypomanic episodes * Pregnant, attempting to become pregnant, or breastfeeding * Diagnosed photosensitivity disorder, retinal disease, or use of medications known to cause significant photosensitivity, at investigator discretion based on disclosed medications * Currently using prescription light therapy, or actively enrolled in another light-related research study * Unable to consent for themselves (participants requiring enrollment by a legally authorized representative are not eligible) * Biomarker sub-study only: acutely unwell, febrile, or reporting acute infectious symptoms on the study day * Biomarker sub-study only: known bleeding diathesis, anticoagulant use other than low-dose aspirin, severe needle phobia, or whole-blood or plasma donation within the prior two weeks * Biomarker sub-study only: member of the study or laboratory team who would otherwise process their own sample * Any condition that, in the judgment of the investigator or attending phlebotomist or nurse, would make participation unsafe

Primary outcome measure(s)

Trial sites (1)

FacilityCityRegionStatus
SOSV New York New York
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT07744711 on ClinicalTrials.gov ↗ ← All trials in the USA